To The Moon
Home
News
TigerAI
Log In
Sign Up
Shibing
+Follow
Posts · 72
Posts · 72
Following · 0
Following · 0
Followers · 0
Followers · 0
Shibing
Shibing
·
2023-05-18
$Tesla Motors(TSLA)$
看
2.23K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-23
Ok
EngageSmart opens for trading at $37, up about 43.6% from IPO price
(Sept 23) EngageSmart Inc. opens for trading at $37, up about 43.6% from IPO price. Company Braintr
EngageSmart opens for trading at $37, up about 43.6% from IPO price
看
2.32K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-22
Ok
Sorry, this post has been deleted
看
2.79K
回复
2
点赞
6
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-21
Ok
U.S. Stock Futures Advance, Airline shares, Carnival stocks rally
(Update: Sept 20, 2021 at 04:49 a.m. ET) (Sept 21) U.S. Stock Futures Advance, Airline shares, Carni
U.S. Stock Futures Advance, Airline shares, Carnival stocks rally
看
2.49K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-20
Oo
3 COVID Stocks That Might Double Soon
Here are three healthcare stocks as nominees for a quick double in 2021.
3 COVID Stocks That Might Double Soon
看
2.32K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-16
Ok
3 COVID Stocks That Might Double Soon
Here are three healthcare stocks as nominees for a quick double in 2021.
3 COVID Stocks That Might Double Soon
看
3.00K
回复
1
点赞
8
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-16
Ok
EV Stocks slipped in premarket trading
EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8%
EV Stocks slipped in premarket trading
看
2.15K
回复
Comment
点赞
5
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-16
Ok
U.S. stocks close lower on worries over recovery, corporate tax hikes
NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing
U.S. stocks close lower on worries over recovery, corporate tax hikes
看
2.07K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-14
Ok
Here's Why Ocugen Is Skyrocketing On Monday
There's both good and bad news for this troubled coronavirus vaccine biotech. What happened Ocugen(N
Here's Why Ocugen Is Skyrocketing On Monday
看
3.27K
回复
1
点赞
6
编组 21备份 2
Share
Report
Shibing
Shibing
·
2021-09-13
OK
Sorry, this post has been deleted
看
3.00K
回复
3
点赞
8
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3554626415127931","uuid":"3554626415127931","gmtCreate":1591534679686,"gmtModify":1614133891012,"name":"Shibing","pinyin":"shibing","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","hatId":"ca_profile_frame_Lm11L6","hatName":"","vip":1,"status":2,"fanSize":10,"headSize":165,"tweetSize":72,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.46%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.99%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":17,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9970633001,"gmtCreate":1684347758003,"gmtModify":1684347760943,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a><v-v data-views=\"0\"></v-v>","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$ </a><v-v data-views=\"0\"></v-v>","text":"$Tesla Motors(TSLA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9970633001","isVote":1,"tweetType":1,"viewCount":2231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863484850,"gmtCreate":1632412498970,"gmtModify":1676530777658,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863484850","repostId":"1159478468","repostType":4,"repost":{"id":"1159478468","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632411695,"share":"https://ttm.financial/m/news/1159478468?lang=&edition=fundamental","pubTime":"2021-09-23 23:41","market":"other","language":"en","title":"EngageSmart opens for trading at $37, up about 43.6% from IPO price","url":"https://stock-news.laohu8.com/highlight/detail?id=1159478468","media":"Tiger Newspress","summary":"(Sept 23) EngageSmart Inc. opens for trading at $37, up about 43.6% from IPO price.\n\nCompany\nBraintr","content":"<p>(Sept 23) <a href=\"https://laohu8.com/S/ESMT\">EngageSmart Inc.</a> opens for trading at $37, up about 43.6% from IPO price.</p>\n<p><img src=\"https://static.tigerbbs.com/835bc9b4ff09e761852f27f75743b887\" tg-width=\"898\" tg-height=\"550\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Company</b></p>\n<p>Braintree, Massachusetts-based EngageSmart was founded to develop a platform that improves customer engagement tailored for certain industry verticals.</p>\n<p>Management is headed by founder and CEO Robert P. Bennett, who has been with the firm since inception and was previously president of Sage Payment Solutions.</p>\n<p>The company's primary offerings include:</p>\n<ul>\n <li>SimplePractice - Wellness</li>\n <li>InvoiceCloud - Government, Utilities and Financial Services</li>\n <li>HealthPay24 - Healthcare</li>\n <li>DonorDrive - Non-profit and Corporate Fundraising</li>\n</ul>\n<p>EngageSmart has received at least $451 million in equity investment from investors including General Atlantic and Summit Partners.</p>\n<p><b>Customer Acquisition</b></p>\n<p>The firm pursues both large enterprise customers and SMB customers via its direct sales force and online service.</p>\n<p>As of June 30, 2021, the firm had served over 68,000 clients in the SMB market and more than 3,000 customers in its Enterprise Solutions segment.</p>\n<p>Selling and Marketing expenses as a percentage of total revenue have dropped as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Selling and Marketing</b></p></td>\n <td><p><b>Expenses vs. Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Percentage</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>32.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>33.1%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>43.1%</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>The Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped slightly to 1.1x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Selling and Marketing</b></p></td>\n <td><p><b>Efficiency Rate</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Multiple</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>1.1</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>1.3</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>The Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory.</p>\n<p>ESMT's most recent calculation was 64% as of June 30, 2021, so the firm is performing well in this regard, per the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Rule of 40</b></p></td>\n <td><p><b>Calculation</b></p></td>\n </tr>\n <tr>\n <td><p>Recent Rev. Growth %</p></td>\n <td><p>59%</p></td>\n </tr>\n <tr>\n <td><p>EBITDA %</p></td>\n <td><p>5%</p></td>\n </tr>\n <tr>\n <td><p>Total</p></td>\n <td><p>64%</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>The firm's dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p>\n<p>The dollar-based net revenue retention rate metric measures how much additional revenue is generated over time from each cohort of customers, so that a figure over 100% means that the company is generating more revenue from the same customer cohort over time, indicating good product/market fit and efficient sales and marketing efforts.</p>\n<p><b>Market & Competition</b></p>\n<p>According to a 2021 marketresearch reportby Mordor Intelligence, the global market for customer engagement solutions was an estimated $15.5 billion in 2020 and is forecast to reach $30.9 billion by 2026.</p>\n<p>This represents a forecast CAGR of 12.65% from 2021 to 2026.</p>\n<p>The main drivers for this expected growth are a growth in technology solutions to improve the customer journey via any device they use to connect with businesses.</p>\n<p>Also, a desire to reduce customer churn rate results in improved business financials and growing valuation.</p>\n<p>Below is a chart showing the variation in customer churn rates in different industries in the U.S. in 2018:</p>\n<p><img src=\"https://static.tigerbbs.com/f1066adb602d05e4e99630aacf61e1c5\" tg-width=\"1060\" tg-height=\"922\" referrerpolicy=\"no-referrer\">Major competitive or other industry participants include:</p>\n<ul>\n <li><p>IBM(NYSE:IBM)</p></li>\n <li><p>Microsoft(NASDAQ:MSFT)</p></li>\n <li><p>Nuance(NASDAQ:NUAN)</p></li>\n <li><p>Oracle(NYSE:ORCL)</p></li>\n <li><p>Salesforce(NYSE:CRM)</p></li>\n <li><p>Avaya(NYSE:AVYA)</p></li>\n <li><p>Calabrio</p></li>\n <li><p>Aspect Software</p></li>\n <li><p>Genesys</p></li>\n <li><p>Verint Systems(NASDAQ:VRNT)</p></li>\n <li><p>NICE Ltd.(NASDAQ:NICE)</p></li>\n <li><p>OpenText</p></li>\n <li><p>Pegasystems(NASDAQ:PEGA)</p></li>\n <li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>EngageSmart's recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Growing topline revenue</p></li>\n <li><p>Increasing gross profit and high gross margin</p></li>\n <li><p>Growing operating profit and net income</p></li>\n <li><p>Increasing cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm's registration statement:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Total Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Total Revenue</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 99,171,000</p></td>\n <td><p>58.6%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 146,557,000</p></td>\n <td><p>77.8%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 82,432,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Profit (Loss)</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 73,673,000</p></td>\n <td><p>61.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 108,964,000</p></td>\n <td><p>89.2%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 57,591,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Margin</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>74.29%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>74.35%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>69.86%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Operating Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Operating Profit (Loss)</p></td>\n <td><p>Operating Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 5,001,000</p></td>\n <td><p>5.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 648,000</p></td>\n <td><p>0.4%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (50,398,000)</p></td>\n <td><p>-61.1%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Net Income (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Net Income (Loss)</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 274,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (6,678,000)</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (53,598,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Cash Flow From Operations</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Cash Flow From Operations</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 12,044,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 19,645,000</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (1,427,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p>(Glossary Of Terms)</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>As of June 30, 2021, EngageSmart had $31.8 million in cash and $151.8 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was $25.2 million.</p>\n<p><b>IPO Details</b></p>\n<p>ESMT intends to sell 13 million shares and selling shareholders will offer 1.55 million shares of common stock at a proposed midpoint price of $24.00 per share for gross proceeds of approximately $349 million, not including the sale of customary underwriter options.</p>\n<p>New potential investor Dragoneer Investment Group has indicated an interest to purchase 2.1 million shares of the offering or about $50.4 million at the proposed midpoint price.</p>\n<p>Assuming a successful IPO at the midpoint of the proposed price range, the company's enterprise value at IPO (ex- underwriter options) would approximate $3.7 billion.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 9.04%. A figure under 10% is generally considered a 'low float' stock which can be subject to significant price volatility.</p>\n<p>Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:</p>\n<blockquote>\n We expect to use the net proceeds of this offering to repay in full the outstanding borrowings of approximately $114.2 million under our Credit Facilities. We currently intend to use the remaining net proceeds from this offering for general corporate purposes, including to fund our growth, acquire complementary businesses, products, services, or technologies, working capital, operating expenses, and capital expenditures.\n</blockquote>\n<blockquote>\n Source: SEC\n</blockquote>\n<p>Management's presentation of the company roadshow isavailable here.</p>\n<p>Regarding outstanding legal proceedings, management did not disclose any legal claims against the firm as of the regulatory filing date.</p>\n<p>Listed underwriters of the IPO are JPMorgan, Goldman Sachs, BofA Securities, and other investment banks.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of the firm's relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Measure [TTM]</b></p></td>\n <td><p><b>Amount</b></p></td>\n </tr>\n <tr>\n <td><p>Market Capitalization at IPO</p></td>\n <td><p>$3,862,956,720</p></td>\n </tr>\n <tr>\n <td><p>Enterprise Value</p></td>\n <td><p>$3,656,695,720</p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>21.09</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>19.96</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>377.37</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$0.00</p></td>\n </tr>\n <tr>\n <td><p>Float To Outstanding Shares Ratio</p></td>\n <td><p>9.04%</p></td>\n </tr>\n <tr>\n <td><p>Proposed IPO Midpoint Price per Share</p></td>\n <td><p>$24.00</p></td>\n </tr>\n <tr>\n <td><p>Net Free Cash Flow</p></td>\n <td><p>$25,236,000</p></td>\n </tr>\n <tr>\n <td><p>Free Cash Flow Yield Per Share</p></td>\n <td><p>0.65%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>58.59%</p></td>\n </tr>\n <tr></tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>As a reference, a potential public comparable would be NICE Ltd.; shown below is a comparison of their primary valuation metrics:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Metric</b></p></td>\n <td><p><b>Nice Ltd.</b></p></td>\n <td><p><b>EngageSmart</b></p></td>\n <td><p><b>Variance</b></p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>11.01</p></td>\n <td><p>21.09</p></td>\n <td><p>91.5%</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>10.67</p></td>\n <td><p>19.96</p></td>\n <td><p>87.1%</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>41.73</p></td>\n <td><p>377.37</p></td>\n <td><p>804.3%</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$3.05</p></td>\n <td><p>$0.00</p></td>\n <td><p>-100.0%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>5.3%</p></td>\n <td><p>58.59%</p></td>\n <td><p>1003.34%</p></td>\n </tr>\n <tr></tr>\n </tbody>\n</table>\n<p>(S-1/A andSeeking Alpha)</p>\n<p><b>Commentary</b></p>\n<p>ESMT is seeking public investment to pay down debt and for its general unspecified corporate growth plans.</p>\n<p>The firm's financials show strong topline revenue growth and gross profit growth, operating profit and a swing to slight net profit along with growing cash flow from operations.</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was a solid $25.2 million.</p>\n<p>Selling and Marketing expenses as a percentage of total revenue have dropped as revenue has increased and its Selling and Marketing efficiency rate dropped to 1.1x in the most recent six-month reporting period.</p>\n<p>The company's Rule of 40 performance was excellent and its dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p>\n<p>The market opportunity for providing customer engagement software to businesses is large and expected to double in size by the end of 2026, so the company will be helped by strong industry growth dynamics.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 20.4% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company's outlook is the ability for larger firms to bundle some of their services into their existing offerings, resulting in downward pricing pressure and greater competition.</p>\n<p>As for valuation, compared to partial competitor NICE, ESMT is growing revenue much faster and so its much higher revenue multiples would appear to be justified.</p>\n<p>Also, the company is growing much faster than competitor Pegasystems, so seems to be taking market share from these and other companies in the customer engagement market.</p>\n<p>Given the firm's strong growth and operating metrics versus its competitors, while the IPO isn't cheap, it is worth consideration.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EngageSmart opens for trading at $37, up about 43.6% from IPO price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEngageSmart opens for trading at $37, up about 43.6% from IPO price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-23 23:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Sept 23) <a href=\"https://laohu8.com/S/ESMT\">EngageSmart Inc.</a> opens for trading at $37, up about 43.6% from IPO price.</p>\n<p><img src=\"https://static.tigerbbs.com/835bc9b4ff09e761852f27f75743b887\" tg-width=\"898\" tg-height=\"550\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Company</b></p>\n<p>Braintree, Massachusetts-based EngageSmart was founded to develop a platform that improves customer engagement tailored for certain industry verticals.</p>\n<p>Management is headed by founder and CEO Robert P. Bennett, who has been with the firm since inception and was previously president of Sage Payment Solutions.</p>\n<p>The company's primary offerings include:</p>\n<ul>\n <li>SimplePractice - Wellness</li>\n <li>InvoiceCloud - Government, Utilities and Financial Services</li>\n <li>HealthPay24 - Healthcare</li>\n <li>DonorDrive - Non-profit and Corporate Fundraising</li>\n</ul>\n<p>EngageSmart has received at least $451 million in equity investment from investors including General Atlantic and Summit Partners.</p>\n<p><b>Customer Acquisition</b></p>\n<p>The firm pursues both large enterprise customers and SMB customers via its direct sales force and online service.</p>\n<p>As of June 30, 2021, the firm had served over 68,000 clients in the SMB market and more than 3,000 customers in its Enterprise Solutions segment.</p>\n<p>Selling and Marketing expenses as a percentage of total revenue have dropped as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Selling and Marketing</b></p></td>\n <td><p><b>Expenses vs. Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Percentage</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>32.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>33.1%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>43.1%</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>The Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped slightly to 1.1x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Selling and Marketing</b></p></td>\n <td><p><b>Efficiency Rate</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Multiple</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>1.1</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>1.3</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>The Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory.</p>\n<p>ESMT's most recent calculation was 64% as of June 30, 2021, so the firm is performing well in this regard, per the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Rule of 40</b></p></td>\n <td><p><b>Calculation</b></p></td>\n </tr>\n <tr>\n <td><p>Recent Rev. Growth %</p></td>\n <td><p>59%</p></td>\n </tr>\n <tr>\n <td><p>EBITDA %</p></td>\n <td><p>5%</p></td>\n </tr>\n <tr>\n <td><p>Total</p></td>\n <td><p>64%</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>The firm's dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p>\n<p>The dollar-based net revenue retention rate metric measures how much additional revenue is generated over time from each cohort of customers, so that a figure over 100% means that the company is generating more revenue from the same customer cohort over time, indicating good product/market fit and efficient sales and marketing efforts.</p>\n<p><b>Market & Competition</b></p>\n<p>According to a 2021 marketresearch reportby Mordor Intelligence, the global market for customer engagement solutions was an estimated $15.5 billion in 2020 and is forecast to reach $30.9 billion by 2026.</p>\n<p>This represents a forecast CAGR of 12.65% from 2021 to 2026.</p>\n<p>The main drivers for this expected growth are a growth in technology solutions to improve the customer journey via any device they use to connect with businesses.</p>\n<p>Also, a desire to reduce customer churn rate results in improved business financials and growing valuation.</p>\n<p>Below is a chart showing the variation in customer churn rates in different industries in the U.S. in 2018:</p>\n<p><img src=\"https://static.tigerbbs.com/f1066adb602d05e4e99630aacf61e1c5\" tg-width=\"1060\" tg-height=\"922\" referrerpolicy=\"no-referrer\">Major competitive or other industry participants include:</p>\n<ul>\n <li><p>IBM(NYSE:IBM)</p></li>\n <li><p>Microsoft(NASDAQ:MSFT)</p></li>\n <li><p>Nuance(NASDAQ:NUAN)</p></li>\n <li><p>Oracle(NYSE:ORCL)</p></li>\n <li><p>Salesforce(NYSE:CRM)</p></li>\n <li><p>Avaya(NYSE:AVYA)</p></li>\n <li><p>Calabrio</p></li>\n <li><p>Aspect Software</p></li>\n <li><p>Genesys</p></li>\n <li><p>Verint Systems(NASDAQ:VRNT)</p></li>\n <li><p>NICE Ltd.(NASDAQ:NICE)</p></li>\n <li><p>OpenText</p></li>\n <li><p>Pegasystems(NASDAQ:PEGA)</p></li>\n <li><p>Others</p></li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>EngageSmart's recent financial results can be summarized as follows:</p>\n<ul>\n <li><p>Growing topline revenue</p></li>\n <li><p>Increasing gross profit and high gross margin</p></li>\n <li><p>Growing operating profit and net income</p></li>\n <li><p>Increasing cash flow from operations</p></li>\n</ul>\n<p>Below are relevant financial results derived from the firm's registration statement:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Total Revenue</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Total Revenue</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 99,171,000</p></td>\n <td><p>58.6%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 146,557,000</p></td>\n <td><p>77.8%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 82,432,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Profit (Loss)</p></td>\n <td><p>% Variance vs. Prior</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 73,673,000</p></td>\n <td><p>61.4%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 108,964,000</p></td>\n <td><p>89.2%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ 57,591,000</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Gross Margin</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Gross Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>74.29%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>74.35%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>69.86%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Operating Profit (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Operating Profit (Loss)</p></td>\n <td><p>Operating Margin</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 5,001,000</p></td>\n <td><p>5.0%</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 648,000</p></td>\n <td><p>0.4%</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (50,398,000)</p></td>\n <td><p>-61.1%</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Net Income (Loss)</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Net Income (Loss)</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 274,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ (6,678,000)</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (53,598,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p><b>Cash Flow From Operations</b></p></td>\n </tr>\n <tr>\n <td><p>Period</p></td>\n <td><p>Cash Flow From Operations</p></td>\n </tr>\n <tr>\n <td><p>Six Mos. Ended June 30, 2021</p></td>\n <td><p>$ 12,044,000</p></td>\n </tr>\n <tr>\n <td><p>2020</p></td>\n <td><p>$ 19,645,000</p></td>\n </tr>\n <tr>\n <td><p>2019</p></td>\n <td><p>$ (1,427,000)</p></td>\n </tr>\n <tr></tr>\n <tr>\n <td><p>(Glossary Of Terms)</p></td>\n </tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>As of June 30, 2021, EngageSmart had $31.8 million in cash and $151.8 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was $25.2 million.</p>\n<p><b>IPO Details</b></p>\n<p>ESMT intends to sell 13 million shares and selling shareholders will offer 1.55 million shares of common stock at a proposed midpoint price of $24.00 per share for gross proceeds of approximately $349 million, not including the sale of customary underwriter options.</p>\n<p>New potential investor Dragoneer Investment Group has indicated an interest to purchase 2.1 million shares of the offering or about $50.4 million at the proposed midpoint price.</p>\n<p>Assuming a successful IPO at the midpoint of the proposed price range, the company's enterprise value at IPO (ex- underwriter options) would approximate $3.7 billion.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 9.04%. A figure under 10% is generally considered a 'low float' stock which can be subject to significant price volatility.</p>\n<p>Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:</p>\n<blockquote>\n We expect to use the net proceeds of this offering to repay in full the outstanding borrowings of approximately $114.2 million under our Credit Facilities. We currently intend to use the remaining net proceeds from this offering for general corporate purposes, including to fund our growth, acquire complementary businesses, products, services, or technologies, working capital, operating expenses, and capital expenditures.\n</blockquote>\n<blockquote>\n Source: SEC\n</blockquote>\n<p>Management's presentation of the company roadshow isavailable here.</p>\n<p>Regarding outstanding legal proceedings, management did not disclose any legal claims against the firm as of the regulatory filing date.</p>\n<p>Listed underwriters of the IPO are JPMorgan, Goldman Sachs, BofA Securities, and other investment banks.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of the firm's relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Measure [TTM]</b></p></td>\n <td><p><b>Amount</b></p></td>\n </tr>\n <tr>\n <td><p>Market Capitalization at IPO</p></td>\n <td><p>$3,862,956,720</p></td>\n </tr>\n <tr>\n <td><p>Enterprise Value</p></td>\n <td><p>$3,656,695,720</p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>21.09</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>19.96</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>377.37</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$0.00</p></td>\n </tr>\n <tr>\n <td><p>Float To Outstanding Shares Ratio</p></td>\n <td><p>9.04%</p></td>\n </tr>\n <tr>\n <td><p>Proposed IPO Midpoint Price per Share</p></td>\n <td><p>$24.00</p></td>\n </tr>\n <tr>\n <td><p>Net Free Cash Flow</p></td>\n <td><p>$25,236,000</p></td>\n </tr>\n <tr>\n <td><p>Free Cash Flow Yield Per Share</p></td>\n <td><p>0.65%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>58.59%</p></td>\n </tr>\n <tr></tr>\n </tbody>\n</table>\n<p>Source: SEC</p>\n<p>As a reference, a potential public comparable would be NICE Ltd.; shown below is a comparison of their primary valuation metrics:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n <tr>\n <td><p><b>Metric</b></p></td>\n <td><p><b>Nice Ltd.</b></p></td>\n <td><p><b>EngageSmart</b></p></td>\n <td><p><b>Variance</b></p></td>\n </tr>\n <tr>\n <td><p>Price / Sales</p></td>\n <td><p>11.01</p></td>\n <td><p>21.09</p></td>\n <td><p>91.5%</p></td>\n </tr>\n <tr>\n <td><p>EV / Revenue</p></td>\n <td><p>10.67</p></td>\n <td><p>19.96</p></td>\n <td><p>87.1%</p></td>\n </tr>\n <tr>\n <td><p>EV / EBITDA</p></td>\n <td><p>41.73</p></td>\n <td><p>377.37</p></td>\n <td><p>804.3%</p></td>\n </tr>\n <tr>\n <td><p>Earnings Per Share</p></td>\n <td><p>$3.05</p></td>\n <td><p>$0.00</p></td>\n <td><p>-100.0%</p></td>\n </tr>\n <tr>\n <td><p>Revenue Growth Rate</p></td>\n <td><p>5.3%</p></td>\n <td><p>58.59%</p></td>\n <td><p>1003.34%</p></td>\n </tr>\n <tr></tr>\n </tbody>\n</table>\n<p>(S-1/A andSeeking Alpha)</p>\n<p><b>Commentary</b></p>\n<p>ESMT is seeking public investment to pay down debt and for its general unspecified corporate growth plans.</p>\n<p>The firm's financials show strong topline revenue growth and gross profit growth, operating profit and a swing to slight net profit along with growing cash flow from operations.</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was a solid $25.2 million.</p>\n<p>Selling and Marketing expenses as a percentage of total revenue have dropped as revenue has increased and its Selling and Marketing efficiency rate dropped to 1.1x in the most recent six-month reporting period.</p>\n<p>The company's Rule of 40 performance was excellent and its dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.</p>\n<p>The market opportunity for providing customer engagement software to businesses is large and expected to double in size by the end of 2026, so the company will be helped by strong industry growth dynamics.</p>\n<p>JPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 20.4% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company's outlook is the ability for larger firms to bundle some of their services into their existing offerings, resulting in downward pricing pressure and greater competition.</p>\n<p>As for valuation, compared to partial competitor NICE, ESMT is growing revenue much faster and so its much higher revenue multiples would appear to be justified.</p>\n<p>Also, the company is growing much faster than competitor Pegasystems, so seems to be taking market share from these and other companies in the customer engagement market.</p>\n<p>Given the firm's strong growth and operating metrics versus its competitors, while the IPO isn't cheap, it is worth consideration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ESMT":"EngageSmart Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159478468","content_text":"(Sept 23) EngageSmart Inc. opens for trading at $37, up about 43.6% from IPO price.\n\nCompany\nBraintree, Massachusetts-based EngageSmart was founded to develop a platform that improves customer engagement tailored for certain industry verticals.\nManagement is headed by founder and CEO Robert P. Bennett, who has been with the firm since inception and was previously president of Sage Payment Solutions.\nThe company's primary offerings include:\n\nSimplePractice - Wellness\nInvoiceCloud - Government, Utilities and Financial Services\nHealthPay24 - Healthcare\nDonorDrive - Non-profit and Corporate Fundraising\n\nEngageSmart has received at least $451 million in equity investment from investors including General Atlantic and Summit Partners.\nCustomer Acquisition\nThe firm pursues both large enterprise customers and SMB customers via its direct sales force and online service.\nAs of June 30, 2021, the firm had served over 68,000 clients in the SMB market and more than 3,000 customers in its Enterprise Solutions segment.\nSelling and Marketing expenses as a percentage of total revenue have dropped as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling and Marketing\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n32.4%\n\n\n2020\n33.1%\n\n\n2019\n43.1%\n\n\n\nSource: SEC\nThe Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped slightly to 1.1x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling and Marketing\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n1.1\n\n\n2020\n1.3\n\n\n\nSource: SEC\nThe Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory.\nESMT's most recent calculation was 64% as of June 30, 2021, so the firm is performing well in this regard, per the table below:\n\n\n\n\nRule of 40\nCalculation\n\n\nRecent Rev. Growth %\n59%\n\n\nEBITDA %\n5%\n\n\nTotal\n64%\n\n\n\nSource: SEC\nThe firm's dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.\nThe dollar-based net revenue retention rate metric measures how much additional revenue is generated over time from each cohort of customers, so that a figure over 100% means that the company is generating more revenue from the same customer cohort over time, indicating good product/market fit and efficient sales and marketing efforts.\nMarket & Competition\nAccording to a 2021 marketresearch reportby Mordor Intelligence, the global market for customer engagement solutions was an estimated $15.5 billion in 2020 and is forecast to reach $30.9 billion by 2026.\nThis represents a forecast CAGR of 12.65% from 2021 to 2026.\nThe main drivers for this expected growth are a growth in technology solutions to improve the customer journey via any device they use to connect with businesses.\nAlso, a desire to reduce customer churn rate results in improved business financials and growing valuation.\nBelow is a chart showing the variation in customer churn rates in different industries in the U.S. in 2018:\nMajor competitive or other industry participants include:\n\nIBM(NYSE:IBM)\nMicrosoft(NASDAQ:MSFT)\nNuance(NASDAQ:NUAN)\nOracle(NYSE:ORCL)\nSalesforce(NYSE:CRM)\nAvaya(NYSE:AVYA)\nCalabrio\nAspect Software\nGenesys\nVerint Systems(NASDAQ:VRNT)\nNICE Ltd.(NASDAQ:NICE)\nOpenText\nPegasystems(NASDAQ:PEGA)\nOthers\n\nFinancial Performance\nEngageSmart's recent financial results can be summarized as follows:\n\nGrowing topline revenue\nIncreasing gross profit and high gross margin\nGrowing operating profit and net income\nIncreasing cash flow from operations\n\nBelow are relevant financial results derived from the firm's registration statement:\n\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 99,171,000\n58.6%\n\n\n2020\n$ 146,557,000\n77.8%\n\n\n2019\n$ 82,432,000\n\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nSix Mos. Ended June 30, 2021\n$ 73,673,000\n61.4%\n\n\n2020\n$ 108,964,000\n89.2%\n\n\n2019\n$ 57,591,000\n\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nSix Mos. Ended June 30, 2021\n74.29%\n\n\n2020\n74.35%\n\n\n2019\n69.86%\n\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nSix Mos. Ended June 30, 2021\n$ 5,001,000\n5.0%\n\n\n2020\n$ 648,000\n0.4%\n\n\n2019\n$ (50,398,000)\n-61.1%\n\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nSix Mos. Ended June 30, 2021\n$ 274,000\n\n\n2020\n$ (6,678,000)\n\n\n2019\n$ (53,598,000)\n\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nSix Mos. Ended June 30, 2021\n$ 12,044,000\n\n\n2020\n$ 19,645,000\n\n\n2019\n$ (1,427,000)\n\n\n\n(Glossary Of Terms)\n\n\n\nSource: SEC\nAs of June 30, 2021, EngageSmart had $31.8 million in cash and $151.8 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was $25.2 million.\nIPO Details\nESMT intends to sell 13 million shares and selling shareholders will offer 1.55 million shares of common stock at a proposed midpoint price of $24.00 per share for gross proceeds of approximately $349 million, not including the sale of customary underwriter options.\nNew potential investor Dragoneer Investment Group has indicated an interest to purchase 2.1 million shares of the offering or about $50.4 million at the proposed midpoint price.\nAssuming a successful IPO at the midpoint of the proposed price range, the company's enterprise value at IPO (ex- underwriter options) would approximate $3.7 billion.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 9.04%. A figure under 10% is generally considered a 'low float' stock which can be subject to significant price volatility.\nPer the firm's most recent regulatory filing, it plans to use the net proceeds as follows:\n\n We expect to use the net proceeds of this offering to repay in full the outstanding borrowings of approximately $114.2 million under our Credit Facilities. We currently intend to use the remaining net proceeds from this offering for general corporate purposes, including to fund our growth, acquire complementary businesses, products, services, or technologies, working capital, operating expenses, and capital expenditures.\n\n\n Source: SEC\n\nManagement's presentation of the company roadshow isavailable here.\nRegarding outstanding legal proceedings, management did not disclose any legal claims against the firm as of the regulatory filing date.\nListed underwriters of the IPO are JPMorgan, Goldman Sachs, BofA Securities, and other investment banks.\nValuation Metrics\nBelow is a table of the firm's relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:\n\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$3,862,956,720\n\n\nEnterprise Value\n$3,656,695,720\n\n\nPrice / Sales\n21.09\n\n\nEV / Revenue\n19.96\n\n\nEV / EBITDA\n377.37\n\n\nEarnings Per Share\n$0.00\n\n\nFloat To Outstanding Shares Ratio\n9.04%\n\n\nProposed IPO Midpoint Price per Share\n$24.00\n\n\nNet Free Cash Flow\n$25,236,000\n\n\nFree Cash Flow Yield Per Share\n0.65%\n\n\nRevenue Growth Rate\n58.59%\n\n\n\n\nSource: SEC\nAs a reference, a potential public comparable would be NICE Ltd.; shown below is a comparison of their primary valuation metrics:\n\n\n\n\nMetric\nNice Ltd.\nEngageSmart\nVariance\n\n\nPrice / Sales\n11.01\n21.09\n91.5%\n\n\nEV / Revenue\n10.67\n19.96\n87.1%\n\n\nEV / EBITDA\n41.73\n377.37\n804.3%\n\n\nEarnings Per Share\n$3.05\n$0.00\n-100.0%\n\n\nRevenue Growth Rate\n5.3%\n58.59%\n1003.34%\n\n\n\n\n(S-1/A andSeeking Alpha)\nCommentary\nESMT is seeking public investment to pay down debt and for its general unspecified corporate growth plans.\nThe firm's financials show strong topline revenue growth and gross profit growth, operating profit and a swing to slight net profit along with growing cash flow from operations.\nFree cash flow for the twelve months ended June 30, 2021, was a solid $25.2 million.\nSelling and Marketing expenses as a percentage of total revenue have dropped as revenue has increased and its Selling and Marketing efficiency rate dropped to 1.1x in the most recent six-month reporting period.\nThe company's Rule of 40 performance was excellent and its dollar-based net revenue retention rate for the year ended December 31, 2020, was 124%, a strong result.\nThe market opportunity for providing customer engagement software to businesses is large and expected to double in size by the end of 2026, so the company will be helped by strong industry growth dynamics.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 20.4% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company's outlook is the ability for larger firms to bundle some of their services into their existing offerings, resulting in downward pricing pressure and greater competition.\nAs for valuation, compared to partial competitor NICE, ESMT is growing revenue much faster and so its much higher revenue multiples would appear to be justified.\nAlso, the company is growing much faster than competitor Pegasystems, so seems to be taking market share from these and other companies in the customer engagement market.\nGiven the firm's strong growth and operating metrics versus its competitors, while the IPO isn't cheap, it is worth consideration.","news_type":1,"symbols_score_info":{"ESMT":0.9}},"isVote":1,"tweetType":1,"viewCount":2316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869578979,"gmtCreate":1632311053491,"gmtModify":1676530748952,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/869578979","repostId":"1146187405","repostType":4,"isVote":1,"tweetType":1,"viewCount":2794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860766891,"gmtCreate":1632215333613,"gmtModify":1676530726706,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860766891","repostId":"1160840483","repostType":4,"repost":{"id":"1160840483","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632214161,"share":"https://ttm.financial/m/news/1160840483?lang=&edition=fundamental","pubTime":"2021-09-21 16:49","market":"us","language":"en","title":"U.S. Stock Futures Advance, Airline shares, Carnival stocks rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1160840483","media":"Tiger Newspress","summary":"(Update: Sept 20, 2021 at 04:49 a.m. ET)\n(Sept 21) U.S. Stock Futures Advance, Airline shares, Carni","content":"<p><i><b>(Update: Sept 20, 2021 at 04:49 a.m. ET)</b></i></p>\n<p>(Sept 21) U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.</p>\n<p><img src=\"https://static.tigerbbs.com/9607d4b938bceb5794ca0672738db43c\" tg-width=\"1230\" tg-height=\"507\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/492800aae703e8bd5f15daf33c8c038e\" tg-width=\"274\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Futures Advance, Airline shares, Carnival stocks rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Futures Advance, Airline shares, Carnival stocks rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-21 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><i><b>(Update: Sept 20, 2021 at 04:49 a.m. ET)</b></i></p>\n<p>(Sept 21) U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.</p>\n<p><img src=\"https://static.tigerbbs.com/9607d4b938bceb5794ca0672738db43c\" tg-width=\"1230\" tg-height=\"507\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/492800aae703e8bd5f15daf33c8c038e\" tg-width=\"274\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160840483","content_text":"(Update: Sept 20, 2021 at 04:49 a.m. ET)\n(Sept 21) U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":2492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860928763,"gmtCreate":1632125011152,"gmtModify":1676530705577,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860928763","repostId":"1195990706","repostType":2,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://ttm.financial/m/news/1195990706?lang=&edition=fundamental","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p>\n<p>Read more to find out why we think <b>Novavax</b>(NASDAQ:NVAX), <b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and <b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p>\n<p><b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p>\n<p>Right now,<b>Moderna</b> enjoys a $169 billion market cap, and <b>BioNTech</b> sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p>\n<p>The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p>\n<p>The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.</p>\n<p>I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p>\n<p><b>2. Sorrento Therapeutics: Don't sleep on this name</b></p>\n<p><b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.</p>\n<p>The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p>\n<p>It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p>\n<p><b>3. InMode stock will spike as the world reopens</b></p>\n<p><b>Patrick Bafuma</b> <b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p>\n<p>Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p>\n<p>And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p>\n<p>As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p>\n<p>Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p>\n<p>With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 16:32 GMT+8 <a href=https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","SRNE":"索伦托医疗","INMD":"InMode Ltd."},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"SRNE":0.9,"INMD":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885606281,"gmtCreate":1631781412643,"gmtModify":1676530634216,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885606281","repostId":"1195990706","repostType":4,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://ttm.financial/m/news/1195990706?lang=&edition=fundamental","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.</p>\n<p>Read more to find out why we think <b>Novavax</b>(NASDAQ:NVAX), <b>Sorrento Therapeutics</b>(NASDAQ:SRNE), and <b>InMode</b>(NASDAQ:INMD)will close out 2021 with a bang.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Multiple catalysts will make Novavax shares jump in 2021</b></p>\n<p><b>Taylor Carmichael(Novavax):</b>Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.</p>\n<p>Right now,<b>Moderna</b> enjoys a $169 billion market cap, and <b>BioNTech</b> sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.</p>\n<p>The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.</p>\n<p>The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.</p>\n<p>I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.</p>\n<p><b>2. Sorrento Therapeutics: Don't sleep on this name</b></p>\n<p><b>George Budwell(Sorrento Therapeutics):</b>The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.</p>\n<p>The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.</p>\n<p>It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.</p>\n<p><b>3. InMode stock will spike as the world reopens</b></p>\n<p><b>Patrick Bafuma</b> <b>(InMode):</b>As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.</p>\n<p>Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.</p>\n<p>And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.</p>\n<p>As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"</p>\n<p>Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.</p>\n<p>With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 16:32 GMT+8 <a href=https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","SRNE":"索伦托医疗","INMD":"InMode Ltd."},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"SRNE":0.9,"INMD":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885606881,"gmtCreate":1631781367343,"gmtModify":1676530634208,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885606881","repostId":"1178217262","repostType":4,"repost":{"id":"1178217262","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631780500,"share":"https://ttm.financial/m/news/1178217262?lang=&edition=fundamental","pubTime":"2021-09-16 16:21","market":"us","language":"en","title":"EV Stocks slipped in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1178217262","media":"Tiger Newspress","summary":"EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8%","content":"<p>EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8% while Lucid rose nearly 2% as BofA called Lucid the 'Tesla/Ferrari of New EV Automakers'.</p>\n<p><img src=\"https://static.tigerbbs.com/294b5ec452d391346819925d05588591\" tg-width=\"405\" tg-height=\"301\" referrerpolicy=\"no-referrer\"></p>\n<p>Cathie Wood’s exchange-traded funds sold more Tesla Inc. shares, taking the total value of the electric vehicle maker’s stock they’ve offloaded this month to about $266 million.</p>\n<p>XPeng launched its third production model, the P5 sedan. A lidar-equipped EV that starts at less than 160,00 Chinese renminbi, or less than $25,000.There are lower-priced EVs on the market, but not with lidar-enabled, advanced driver assistance systems and not with range of the P5.The stock isn’t reacting too positively to the announcement.</p>\n<p>Bank of America predicts 50% gain in Lucid, compares EV maker to Tesla and Ferrari.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks slipped in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks slipped in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-16 16:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8% while Lucid rose nearly 2% as BofA called Lucid the 'Tesla/Ferrari of New EV Automakers'.</p>\n<p><img src=\"https://static.tigerbbs.com/294b5ec452d391346819925d05588591\" tg-width=\"405\" tg-height=\"301\" referrerpolicy=\"no-referrer\"></p>\n<p>Cathie Wood’s exchange-traded funds sold more Tesla Inc. shares, taking the total value of the electric vehicle maker’s stock they’ve offloaded this month to about $266 million.</p>\n<p>XPeng launched its third production model, the P5 sedan. A lidar-equipped EV that starts at less than 160,00 Chinese renminbi, or less than $25,000.There are lower-priced EVs on the market, but not with lidar-enabled, advanced driver assistance systems and not with range of the P5.The stock isn’t reacting too positively to the announcement.</p>\n<p>Bank of America predicts 50% gain in Lucid, compares EV maker to Tesla and Ferrari.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","LI":"理想汽车","NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178217262","content_text":"EV Stocks slipped in premarket trading.Tesla,Nio,Xpeng Motors and Li Auto fell between 0.5% and 2.8% while Lucid rose nearly 2% as BofA called Lucid the 'Tesla/Ferrari of New EV Automakers'.\n\nCathie Wood’s exchange-traded funds sold more Tesla Inc. shares, taking the total value of the electric vehicle maker’s stock they’ve offloaded this month to about $266 million.\nXPeng launched its third production model, the P5 sedan. A lidar-equipped EV that starts at less than 160,00 Chinese renminbi, or less than $25,000.There are lower-priced EVs on the market, but not with lidar-enabled, advanced driver assistance systems and not with range of the P5.The stock isn’t reacting too positively to the announcement.\nBank of America predicts 50% gain in Lucid, compares EV maker to Tesla and Ferrari.","news_type":1,"symbols_score_info":{"LCID":0.9,"XPEV":0.9,"LI":0.9,"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885003623,"gmtCreate":1631736185462,"gmtModify":1676530620639,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885003623","repostId":"1148341685","repostType":4,"repost":{"id":"1148341685","kind":"news","pubTimestamp":1631660884,"share":"https://ttm.financial/m/news/1148341685?lang=&edition=fundamental","pubTime":"2021-09-15 07:08","market":"us","language":"en","title":"U.S. stocks close lower on worries over recovery, corporate tax hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1148341685","media":"Reuters","summary":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing","content":"<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.</p>\n<p>Optimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.</p>\n<p>So far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.</p>\n<p>“There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”</p>\n<p>The advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.</p>\n<p>“We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”</p>\n<p>The CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.</p>\n<p>U.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]</p>\n<p>The long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.</p>\n<p>The Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.</p>\n<p>All 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.</p>\n<p>Apple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.</p>\n<p>Intuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.</p>\n<p>CureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.</p>\n<p>The S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.</p>\n<p>Volume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks close lower on worries over recovery, corporate tax hikes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks close lower on worries over recovery, corporate tax hikes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 07:08 GMT+8 <a href=https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/usa-stocks/u-s-stocks-close-lower-on-worries-over-recovery-corporate-tax-hikes-idUSKBN2GA0W9","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148341685","content_text":"NEW YORK (Reuters) - Wall Street lost ground on Tuesday as economic uncertainties and the increasing likelihood of a corporate tax rate hike dampened investor sentiment and prompted a broad sell-off despite signs of easing inflation.\nOptimism faded throughout the session, reversing an initial rally following the Labor Department’s consumer price index report. All three major U.S. stock indexes ended in negative territory in a reminder that September is a historically rough month for stocks.\nSo far this month the S&P 500 is down nearly 1.8% even as the benchmark index has gained over 18% since the beginning of the year.\n“There is a possibility that the market is simply ready to go through an overdue correction,” said Sam Stovall, chief investment strategist at CFRA Research in New York. “From a seasonality perspective, September tends to be the window dressing period for fund managers.”\nThe advent of the highly contagious Delta COVID variant has driven an increase in bearish sentiment regarding the recovery from the global health crisis, and many now expect a substantial correction in stock markets by the end of the year.\n“We’re still in a corrective mode that people have been calling for months,” said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. “Economic data points have been missing estimates, and that has coincided with the rise in the Delta variant.”\nThe CPI report delivered a lower-than-consensus August reading, a deceleration that supports Federal Reserve Chairman Jerome Powell’s assertion that spiking inflation is transitory and calms market fears that the central bank will begin tightening monetary policy sooner than expected.\nU.S. Treasury yields dropped on the data, which pressured financial stocks, and investor favor pivoted back to growth at the expense of value. [US/]\nThe long expected corporate tax hikes, to 26.5% from 21% if Democrats prevail, are coming nearer to fruition with U.S. President Joe Biden’s $3.5 trillion budget package inching closer to passage.\nThe Dow Jones Industrial Average fell 292.06 points, or 0.84%, to 34,577.57; the S&P 500 lost 25.68 points, or 0.57%, at 4,443.05; and the Nasdaq Composite dropped 67.82 points, or 0.45%, to 15,037.76.\nAll 11 major sectors in the S&P 500 ended the session red, with energy and financials suffering the largest percentage drops.\nApple Inc unveiled its iPhone 13 and added new features to its iPad and Apple Watch gadgets in its biggest product launch event of the year as the company faces increased scrutiny in the courts over its business practices. Its shares closed down 1.0% and were the heaviest drag on the S&P 500 and the Nasdaq.\nIntuit Inc gained 1.9% following the TurboTax maker’s announcement that it would acquire digital marketing company Mailchimp for $12 billion.\nCureVac slid 8.0% after the German biotechnology company canceled manufacturing deals for its experimental COVID-19 vaccine.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.25-to-1 ratio; on Nasdaq, a 2.40-to-1 ratio favored decliners.\nThe S&P 500 posted two new 52-week highs and two new lows; the Nasdaq Composite recorded 50 new highs and 107 new lows.\nVolume on U.S. exchanges was 10.07 billion shares, compared with the 9.38 billion average over the last 20 trading days.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2070,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886588732,"gmtCreate":1631605678426,"gmtModify":1676530587946,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886588732","repostId":"1133790240","repostType":4,"repost":{"id":"1133790240","kind":"news","pubTimestamp":1631605138,"share":"https://ttm.financial/m/news/1133790240?lang=&edition=fundamental","pubTime":"2021-09-14 15:38","market":"us","language":"en","title":"Here's Why Ocugen Is Skyrocketing On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1133790240","media":"Motley Fool","summary":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(N","content":"<p>There's both good and bad news for this troubled coronavirus vaccine biotech.</p>\n<p><b>What happened</b></p>\n<p><b>Ocugen</b>(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.</p>\n<p><b>So what</b></p>\n<p>An EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/303e002c71ec48a633f9aeed23a7c925\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Now what</b></p>\n<p>While the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.</p>\n<p>The company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Ocugen Is Skyrocketing On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Ocugen Is Skyrocketing On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 15:38 GMT+8 <a href=https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133790240","content_text":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.\nSo what\nAn EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.\nIMAGE SOURCE: GETTY IMAGES.\nNow what\nWhile the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.\nThe company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":3270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888746229,"gmtCreate":1631533724561,"gmtModify":1676530567748,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"themes":[],"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/888746229","repostId":"2167630550","repostType":4,"isVote":1,"tweetType":1,"viewCount":3001,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}